1. Home
  2. STHO vs GLSI Comparison

STHO vs GLSI Comparison

Compare STHO & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STHO

Star Holdings Shares of Beneficial Interest

N/A

Current Price

$8.01

Market Cap

104.6M

Sector

Real Estate

ML Signal

N/A

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$27.71

Market Cap

123.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STHO
GLSI
Founded
N/A
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
104.6M
123.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
STHO
GLSI
Price
$8.01
$27.71
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$50.00
AVG Volume (30 Days)
65.3K
732.2K
Earning Date
02-18-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$117,547,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.06
$7.78
52 Week High
$9.57
$34.10

Technical Indicators

Market Signals
Indicator
STHO
GLSI
Relative Strength Index (RSI) 47.93 55.40
Support Level $7.53 $26.51
Resistance Level $8.27 $32.66
Average True Range (ATR) 0.31 4.26
MACD -0.11 -0.34
Stochastic Oscillator 30.97 55.32

Price Performance

Historical Comparison
STHO
GLSI

About STHO Star Holdings Shares of Beneficial Interest

Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: